Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 9.5%. This drop was worse than the S&P 500’s 2.3% loss.
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on.
But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the healthcare technology for providers stocks, including Phreesia (NYSE:PHR) and its peers.
Healthcare technology company Phreesia (NYSE:PHR) beat Wall Street’s revenue expectations in Q4 CY2024, with sales up 15.4% year on year to $109.7 million. The company expects the full year’s revenue to be around $477 million, close to analysts’ estimates. Its GAAP loss of $0.11 per share was 35% above analysts’ consensus estimates.
